[Congressional Record Volume 142, Number 139 (Tuesday, October 1, 1996)]
[Extensions of Remarks]
[Page E1886]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                    PROSTATE CANCER AWARENESS MONTH

                                 ______
                                 

                      HON. RODNEY P. FRELINGHUYSEN

                             of new jersey

                    in the house of representatives

                       Monday, September 30, 1996

  Mr. FRELINGHUYSEN. Mr. Speaker, in recognition of Prostate Cancer 
Awareness Month, I commend to your attention a patient education 
conference that was held earlier this year in the 11th Congressional 
District--Prostate Cancer: Today and Tomorrow. Cohosted by the American 
Foundation for Urologic Disease, Morristown Memorial Hospital and the 
Prostate Cancer Support Group of Morristown Memorial Hospital, it was 
an effective grassroots effort to warn and educate local residents on 
the importance of early detection of and continued research into 
prostate cancer.
  According to the American Cancer Society, prostate cancer is the 
greatest cancer risk for American men, and over 317,000 males will be 
diagnosed with this type of cancer in 1996. It is vital that prostate 
cancer be recognized as a serious threat to American men and their 
families.
  Increased awareness of health issues, improved detection and testing 
techniques, and national awareness programs for this disease have all 
played significant roles in increasing public knowledge of prostate 
cancer.
  There are a number of individuals and organizations I want to 
recognize for holding such an important conference:
  First, Hon. Dean A. Gallo, the former Congressman of New Jersey's 
11th Congressional District, died of prostate cancer on November 6, 
1994. His widow, Mrs. Betty Gallo, is now a trustee of the Dean Gallo 
Foundation and she instituted the Dean Gallo Prostate Cancer Research 
Scholarship Fund. This scholarship fund will help fund career 
investigators who are committed to prostate cancer research in the 
State of New Jersey.
  Second, I commend the American Foundation for Urologic Disease, a 
charitable organization, whose mission is to prevent and find a cure 
for urologic diseases through the expansion of research, education and 
public awareness. For over 20 years, the Research Scholar Program of 
the AFUD has funded over 300 urologic researchers as they established 
their scientific careers. Over 98 percent of the investigators have 
continued in these career paths.
  Third, Morristown Memorial Hospital, a not-for-profit hospital 
serving northern New Jersey, for its leadership in the field. Founded 
in 1892, it has expanded in size and services to become a 599-bed 
medical center and the third largest in the State. It is a major 
teaching hospital, affiliated with Columbia University's College of 
Physicians and Surgeons. Its regional Cancer Center is affiliated with 
the Cancer Institute of New Jersey in New Brunswick and offers 
expertise in surgical, urologic, medical, radiation, and gynecologic 
oncology specialties. Center highlights include clinical trails, 
cytogenetics, and patient support programs.
  Fourth, the Morristown Memorial Prostate Cancer Support Group which 
is chaired by Mr. Peter Doherty, a prostate cancer survivor. Over 75 
persons, including physicians and medical professionals, prostate 
cancer survivors, their partners and families and friends gather to 
exchange information and provide support, encouragement and hope.

  Finally, I would also like to commend the participants of Prostate 
Cancer: Today and Tomorrow, outstanding physicians and an organization 
whose research is making significant inroads in the field of prostate 
cancer. They include:
  E. David Crawford, M.D. professor and chairman, Division of Urology 
of Colorado Health Sciences Center, Denver, CO. He is also chairman of 
the Prostate Cancer Education Council [PCEC], national sponsor of 
Prostate Cancer Awareness Week.
  Charles Myers, M.D., was chief of the Clinical Pharmacology Branch of 
the National Cancer Institute, where he directed clinical trials of 
drugs used in the treatment of advanced prostate cancer.
  William H. Hait, M.D., Ph.D., director of the Cancer Institute of New 
Jersey.
  Arthur Israel, M.D. is chief, Section of Urology, Morristown Memorial 
Hospital. Dr. Israel is a member of the American Foundation for 
Urologic Disease and the American Urological Association. He is 
currently president of the New Jersey Urological Society.
  Schering Oncology Biotech, a corporation headquartered in Kenilworth, 
NJ and TAP Pharmaceutical, Inc. of Deerfield, IL for providing 
educational grants for prostate cancer research.
  All those who participated in Prostate Cancer: Today and Tomorrow 
made a powerful impact on patients, physicians, medical institutions, 
research and educational foundations, and industry to collaborate and 
provide accurate medical information to prostate cancer victims, 
survivors, and their families. I salute their work.

                          ____________________